hotspot -WSS

hotspot

author：fashion 2025-08-12 09:09:04 - browse：1

Christine Kao/STAT

The Food and Drug Administration’s approval on Friday of two gene therapies for sickle cell disease sets up what could be an intense competition between Bluebird Bio, maker of Lyfgenia, and the partnership of Vertex Pharmaceuticals and CRISPR Therapeutics, whose drug is Casgevy.

For the first time, physicians and patients will have a choice of potentially curative treatments for an inherited disease that affects nearly 100,000 Americans.

The Vertex/CRISPR team would seem to have the edge. As the first CRISPR-based therapy, Casgevy has the advantage of being powered by the latest and buzziest biological technology, though some physicians and patients may be more comfortable with the lentiviral vector technology behind Lyfgenia, which dates back to the 1990s — even with a “black box” warning of a risk of blood cancer added to its label.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Key Senate panel to consider PBM, drug pricing reform package

entertainment

hotspot

WSS

Readout LOUD podcast: ESMO highlights & Roivant's big deal

Medicare must police algorithms in Medicare Advantage, Dems say

Brain injuries and the importance of a second opinion

Inari Medical to buy amputation prevention company LimFlow

Explaining an after

In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

knowledge

hotspot

hotspot

As demand for Covid shots wanes, Moderna seeks its next success

Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

At least 13 dead in Texas as scorching temps continue

How neuroscience research could help beat back brain cancer

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

STAT Readout: The latest on Wegovy, Mounjaro, and Covid shots

Medical leaders decry Supreme Court decision on affirmative action

Gene therapy’s promise and the high cost of hope

Psychedelics group wrestles with new pharma identity

Inari Medical to buy amputation prevention company LimFlow

focus

Live blog: Hearing on CRISPR

Gene therapy’s promise and the high cost of hope

After Sarepta trial failure, Duchenne families brace for more debate

Sarepta Duchenne therapy fails to meet primary endpoint in trial

Medicare must police algorithms in Medicare Advantage, Dems say

Prime Medicine says its gene editing passes test in monkeys

entertainment

hotspot

hotspot

Wikipedia